MedPath

A PROSPECTIVE OBSERVATIONAL STUDY COMPARING THREE DIFFERENT TREATMENT MODALITIES IN PRIMARY MEMBRANOUS NEPHROPATHY

Not Applicable
Conditions
Health Condition 1: N042- Nephrotic syndrome with diffuse membranous glomerulonephritis
Registration Number
CTRI/2019/07/020113
Lead Sponsor
IPGMER AND SSKM HOSPITAL KOLKATA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Biopsy proven PMN of age group 18-70 years, fulfilling the criteria for immunosuppression therapy .

2.Fulfilling the criteria for immunosuppression therapy - Urinary protein excretion persistently exceeds 4 g/d AND remains at over 50% of the baseline value AND does not show progressive decline during antihypertensive and antiproteinuric therapy during an observation period of at least 6 months or severe disabling or life threatning symptoms related to the nephrotic syndrome.

3.SCr has risen by 30% or more within 6 to 12 months from the time of diagnosis but the eGFR is not less than 25 ml/min per 1.73m2 AND this change is not explained by superimposed complications.

Exclusion Criteria

1.Patients with active infection.

2.Diabetes mellitus.

3.Hepatitis B/C or human immunodeficiency virus infection.

4.Liver function abnormalities.

5.Neoplasia.

6.Chronic Diarrhoea.

7.Pregnancy.

8.Patients not willing for contraception.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
a)Non inferiority of individual cohorts in inducing complete or partial remission in proteinuriaTimepoint: 1 YEAR
Secondary Outcome Measures
NameTimeMethod
a)Sensitivity of anti PLA2R Ab in predicting partial or complete remission in 3 arms at 6 /12/24/30 months of initiation of therapy. <br/ ><br> <br/ ><br>b) Estimated glomerular filtration rate (eGFR) at the completion of therapy <br/ ><br> <br/ ><br> <br/ ><br>Timepoint: 1 YEAR
© Copyright 2025. All Rights Reserved by MedPath